Legislation In Florida Seeks To Increase Access To Genetic Testing

Susan G. Komen^® Applauds Bill Introduction; Urges Quick Passage

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) for introducing legislation that would eliminate financial barriers for patients requiring clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.

Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth. In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation. The lifetime risk of breast cancer increases 20-49% for women with moderate risk inherited gene mutations and 50% or more for women with high-risk inherited gene mutations.

SB 1372, introduced by Sen. Rodriguez, and HB 1399, introduced by Rep. Woodson, eliminate the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.

“This legislation ensures patients have information on their lifetime cancer risk and access to needed risk reduction and treatment strategies,” said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen. “Understanding cancer risk shouldn’t depend on a patient’s financial means. This legislation helps to eliminate financial barriers, empowering individuals and their family members with essential knowledge to make informed decisions about their health.”

“This bill helps families with a history of cancer to find targeted treatment and prevention. I am excited to sponsor this bill for all Floridians,” said Sen. Rodriguez.

Identification of inherited cancer risk can help guide decisions regarding recommended screenings for the early detection of cancer, personalized cancer treatments and risk-reducing medical treatments. Studies have shown an estimated 83% of eligible patients that underwent multigene panel testing had changes to their medical management, including modifications in follow-up and chemotherapy strategy.

“Early detection is critical to those who have a family history of cancer; this legislation will bring the State of Florida one step closer to detecting all cancers early. Our number one priority must be centered around prevention and early detection in order to save lives,” said Rep. Woodson.

About Susan G. Komen^®

Susan G. Komen^® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.